Therapy Areas: Oncology
Kite plans to build new California facility
18 July 2019 -

Kite, a Gilead Company (Nasdaq: GILD), is planning to construct a new 67,000-square-foot facility in Oceanside, California, it was reported yesterday.

The facility is to develop and manufacture viral vectors, a critical starting material in the production of cell therapies. It is based on the company's present state-of-the-art manufacturing capabilities to deliver innovative cell therapies for people with cancer, including Yescarta (axicabtagene ciloleucel), Kite's first commercially available chimeric antigen receptor T (CAR T) cell therapy, and investigational T cell receptor (TCR) and tumour neoantigen targeting cell therapies being assessed in solid tumours.

Tim Moore, executive vice president of Technical Operations at Kite, said, 'The new viral vector facility in Oceanside is an example of our continued investment in achieving technical advances that will help meet the needs of people living with cancer today and in the future. Viral vectors are one of the key components in cell therapy production, however, the industry's current development and manufacturing capabilities are not widely established and supply is limited. By pursuing our own viral vector facility, we will be able to advance viral vector development and supply to allow for accelerated process development of current CAR T and future pipeline therapies, while continuing to partner with external suppliers.'